> Details

Horak, Peter; Leichsenring, Jonas; Goldschmid, Hannah; Kreutzfeldt, Simon; Kazdal, Daniel; Teleanu, Veronica; Endris, Volker; Gieldon, Laura; Allgäuer, Michael; Volckmar, Anna‐Lena; Dikow, Nicola; Renner, Marcus; Kirchner, Martina; Penzel, Roland; Ploeger, Carolin; Brandt, Regine; Seker‐Cin, Huriye; Budczies, Jan; Heilig, Christoph E.; Neumann, Olaf; Schaaf, Christian P.; Schirmacher, Peter; Fröhling, Stefan; Stenzinger, Albrecht

Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine
  • Contributor: Horak, Peter; Leichsenring, Jonas; Goldschmid, Hannah; Kreutzfeldt, Simon; Kazdal, Daniel; Teleanu, Veronica; Endris, Volker; Gieldon, Laura; Allgäuer, Michael; Volckmar, Anna‐Lena; Dikow, Nicola; Renner, Marcus; Kirchner, Martina; Penzel, Roland; Ploeger, Carolin; Brandt, Regine; Seker‐Cin, Huriye; Budczies, Jan; Heilig, Christoph E.; Neumann, Olaf; Schaaf, Christian P.; Schirmacher, Peter; Fröhling, Stefan; Stenzinger, Albrecht
  • imprint: Wiley, 2022
  • Published in: Genes, Chromosomes and Cancer
  • Language: English
  • DOI: 10.1002/gcc.22987
  • ISSN: 1045-2257; 1098-2264
  • Keywords: Cancer Research ; Genetics
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title><jats:p>Modern concepts in precision cancer medicine are based on increasingly complex genomic analyses and require standardized criteria for the functional evaluation and reporting of detected genomic alterations in order to assess their clinical relevance. In this article, we propose and address the necessary steps in systematic variant evaluation consisting of bioinformatic analysis, functional annotation and clinical interpretation, focusing on the latter two aspects. We discuss the role and clinical application of current variant classification systems and point out their scope and limitations. Finally, we highlight the significance of the molecular tumor board as a platform for clinical decision‐making based on genomic analyses.</jats:p>